A new oral medication to treat patients in the early stages of multiple sclerosis has shown considerable promise in two clinical trials, researchers announced on Wednesday.The medication is on track to become just the third oral drug available to M.S. patients, and potentially the safest and most ef

Investors cheered the news, sending shares of the drugmaker soaring 50 percent to $4.59 on the Nasdaq on Friday afternoon.The Phase 2 trial, involving 121 previously treated non-small cell lung cancer patients, found that those given a lower dose of bavituximab plus chemotherapy lived for a median o

ROONGNAPA KHAMPANG1,2, SAWITRI ASSANANGKORNCHAI1 & YOT TEERAWATTANANON2 1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, and 2Health Intervention and Technology Assessment Program, Department of Health, Ministry of Public Health, Nonthaburi, Tha

(Reuters Health) – There’s more evidence that the new formulation of OxyContin, the time-release version of oxycodone, is discouraging abuse of the powerful drug.But the reformulation, introduced in August 2010 to make it harder to crush the medicine into powder, limiting the ability to snort, injec

GIULIA GRECOa,*, PAULA LORGELLYb and INTHIRA YAMABHAIc a London School of Hygiene & Tropical Medicine, London, UK b Centre for Health Economics, Monash University, Melbourne, Victoria, Australia c Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangko

(Reuters) – Swiss drugmaker Novartis told India’s top court it had demonstrated the improved efficacy of its cancer drug Glivec as the final hearing began on Tuesday of a patent case that could change the rules for the country’s healthcare sector.A patent would recognize Novartis’ property rights, i

(Reuters) – An experimental drug from Novartis may help up to half of heart failure patients for whom no effective treatment is available, although the evidence so far is indirect.Results of a mid-stage clinical trial of the drug known as LCZ696, unveiled on Sunday, gauged its effectiveness by measu

To understand the digital health landscape in different countries from national strategy and regulation to HTA evaluation, adoption, and challenges. The objective is to use this information to better inform digital health policy in Thailand as well as to create a reference case to conduct HTA for digital health technologies.

K. Chittawatanarat a, *, K. Tosanguan b, U. Chaikledkaew b, c, S. Tejavanija d, Y. Teerawattananon b a Division of Trauma and Critical Care, Department of Surgery, Faculty of Medicine, Maharaj Nakorn Chiang Mai Hospital, Intawarorod Road, Sripume, Chiang Mai University, Chiang Mai 50200, Thailand

หากคุณมีผลงานที่ยกระดับสุขภาพ และมีระดับความพร้อมทางเทคโนโลยี (Technology Readiness Level: TRL) ระดับ 5 – 9 เราขอเชิญให้คุณร่วมประกวดโดยส่ง Abstract แนะนำนวัตกรรมที่กำลังวิจัยและพัฒนา เพื่อค้นหาสุดยอดนวัตกรรมด้านการแพทย์ในงาน “MIDAS Medical Innovation Hackathon 2025” ที่จะจัดขึ้นในวันที่ 15-16 กุมภา